<DOC>
	<DOCNO>NCT02485431</DOCNO>
	<brief_summary>This Phase 1 , single-center , single-dose , randomize , 5-period crossover study design assess comparative bioavailability food effect deflazacort . A total 45 subject randomly assign receive 1 5 treatment sequence . Each dose sequence enrol parallel subject receive 5 treatment crossover fashion .</brief_summary>
	<brief_title>Food Effect Bioavailability Deflazacort Formulations Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Deflazacort</mesh_term>
	<criteria>Healthy male female ≥ 18 ≤ 55 time screen . Body mass index ( BMI ) ≥ 18.0 ≤ 32.0 kg/m2 , inclusive , screen Day 1 . Women nonchildbearing potential , define tubal ligation , hysterectomy , postmenopausal ( amenorrhea &gt; 1 year ; confirm FSH ) , oophorectomy . Males sexually active whose partner females childbearing potential must agree use condom screen 90 day last dose study drug . Males must agree donate sperm screen 90 day last dose study drug . Subjects must healthy without clinically significant abnormality assess review medical surgical history , physical examination , vital sign measurement , electrocardiogram ( ECG ) , laboratory evaluation conduct screen visit CPU admission . Subjects must nonsmoker , define abstain tobacco nicotinecontaining product ( eg , cigarette , chew tobacco , snuff , nicotine patch , electronic cigarette ) 3 month prior screen . Positive pregnancy test lactating . History presence condition , judgment investigator , know interfere absorption , distribution , metabolism , excretion drug . History presence condition may place subject increase risk determine investigator . History presence hypersensitivity idiosyncratic reaction study drug relate compound ( eg , steroid formulation include lactose ) . History surgery major trauma within 12 week screen , surgery plan study . History alcohol abuse , illicit drug use , significant mental illness , physical dependence opioid , history drug abuse addiction within 12 month screen . Use prescription medication within 14 day drug inhibit study drug specific cytochrome P450 ( ) within 14 day drug induce specific cytochrome P450s , include St. John 's Wort , within 28 day , 5 halflives , whichever longer , administration first dose study drug throughout study . Use thecounter ( OTC ) drug ( include herbal preparation ) within 7 day 5 halflives , whichever longer , prior administration first dose study drug throughout study . Has take investigational drug , include deflazacort related compound , participate clinical study within 30 day 5 halflives investigational drug 's PK , pharmacodynamic , biological activity , whichever longer , prior first dose study drug study . Has receive immunosuppressive agent , coal tar , and/or radiation therapy within 30 day prior first dose study drug . Has receive injectable corticoid 12 week prior first dose study drug oral form corticoid 30 day prior first dose study drug . Has receive live liveattenuated vaccine within 30 day prior first dose study drug and/or intend receive one study . Significant blood loss ( &gt; 450 mL ) donate 1 unit blood plasma within 6 week prior study participation . Positive urine drug abuse , alcohol breath test , urine cotinine screen . Positive screen human immunodeficiency virus ( HIV ) 1 HIV2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . Estimated creatinine clearance &lt; 80 mL/min use CockcroftGault equation . QTcF interval &gt; 450 msec screening . Unwilling unable consume standardize meal . Unwilling unlikely comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>